

International Journal of Environmental Research and Public Health





Designing Effective Warnings about Addiction on the Patient Information Leaflet of Over-the-Counter Codeine Sold in England to University Students

Jianan Zhao ^{1,†}, Yun Chen ^{2,†}, Ting Han ^{1,*} and Stephen Westland ²

- ¹ School of Design, Shanghai Jiao Tong University, Shanghai 200240, China; jzhao2@cca.edu
- ² School of Design, University of Leeds, Leeds LS2 9JT, UK; sdyc@leeds.ac.uk (Y.C.); S.Westland@leeds.ac.uk (S.W.)
- * Correspondence: hanting@sjtu.edu.cn; Tel.: +86-139-1609-9300
- + The authors contributed equally to this manuscript.

Received: 22 June 2020; Accepted: 24 July 2020; Published: 29 July 2020



Abstract: (1) Background: The harm of misusing over-the-counter (OTC) codeine-containing medicines among university students in England is being increasingly recognized. Based on English university students, this paper aims to study the importance of information design on information communication, explore methods for effective warning design, and investigate university students' perception of OTC codeine. (2) Methods: The effective warning design is addressed through case studies, answering correctness by the heat map generated from the eye-tracking experiment (ETE), and the total time spent on the tasks. User perceptions are made though online surveys. (3) Results: Information design significantly affects the way user processes information. Therefore, two emphasized warnings displayed in the headline, and the "possible side effect (PSE)" sections and warning signs of addiction presented under the PSE are suggested as effective ways to display warnings. For students' perception of OTC codeine, 80% of university students are unfamiliar with the substance. After reading the patient information leaflets (PILs), 47% recommended tight regulation on codeine. (4) Conclusions: The misuse of OTC codeine could be a potential problem among English university students. The design of the PIL significantly influences the chance of unintentional medicine misuse. The display of warnings on the PILs of OTC codeine should be redesigned for better understanding.

Keywords: patient education; medication management and safety; university students; codeine; patient information leaflet; over the counter

1. Introduction

With the potential harm of over-the-counter (OTC) codeine being increasingly acknowledged, a regulation on OTC codeine-containing analgesics was implemented in 2014. A warning term "Can cause addiction. For three days use only" and the warning signs of addiction were mandatory for every patient information leaflet (PIL) of OTC codeine-containing analgesics. However, without a further indication of where and how to display warnings about addiction, the effects of this regulation remain uncertain and limited [1,2].

OTC medicine is usually considered safe to use and available for self-medication [1,3]. Even though OTC medicines are comparably safe and mild in effects, the misuse of medicine, which was proven not rare in the UK, can still lead to severe consequences such as addiction and fatality [4–6]. This situation has raised concern since medicines such as OTC codeine, the most widely used opioid medicine, is very likely to cause harm [7–9]. Codeine, an opioid pain reliever, is available on prescription, or in

lower-strength OTC medicines as a companion to other ingredients such as ibuprofen, caffeine, and paracetamol since it is useful in extending the duration of effects [10–14]. However, the misuse and abuse of OTC codeine-containing medicines can lead to not only addiction caused by codeine but can also lead to renal and liver damage caused by ibuprofen and paracetamol [11,15–18]. Besides, the consumption of codeine could lead to long-term use and dependence on opioids or other addictive substances such as heroin [5,8,19–22].

Codeine misuse and abuse are potentially harmful to individuals, societies, and the economy. Codeine misuse can be especially problematic for the United Kingdom since 44.2 tons of codeine was consumed in the UK in 2016, which was the second-biggest consumer of codeine in the world [21,23]. Among all English nationals, university students are at high risk of misusing OTC codeine, since the university students were proven more likely to misuse and abuse medicines compared to other adults [24,25]. However, insufficient attention was paid to drug intervention of English university students [26].

With increasing awareness of the severe outcomes of codeine misuse, interventions on the production and sale of codeine-containing medicines, including direct pharmacy intervention and online monitoring have been proposed and adopted in England [14]. However, it has been shown that a majority of people in England were not fully aware of the potential risks when they started using codeine-containing medicines [14,16,26]. Therefore, more efforts on patient education is needed, since patient education is effective in preventing medicine misuse [26–32].

For patient education, patient information leaflets (PILs) (a package insert that is mandatory for all medications sold in England) was rated the most reliable and essential source of side effects of medication [33,34]. Accordingly, a tightened regulation on the PIL of OTC codeine was published by the UK government in 2014 [35,36]. The term "Can cause addiction. For three days use only" and an indication on the signs of addiction is demanded for every PIL [2]. However, without further indications of where and how to display this information, the effects of this regulation remain unknown and are potentially limited. Under the circumstances where information design is found influential to the accuracy and amount of information acquired by readers, the investigation on the displacement of warnings about addiction is crucial for increasing public awareness and decreasing codeine misuse [37–39].

Therefore, utilizing a sample from English university students, the aims of the research were: (1) to investigate how essential the information design is for effective communication, (2) to identify an effective way to display warnings about addiction on the PILs of OTC codeine, and (3) to study English students' attitudes and perceptions of OTC codeine-containing medicines.

To achieve these research aims, the research started with two case studies, one offline and one online, to assess the availability of OTC codeine among English university students and collect samples for the following experiment. Then an eye-tracking experiment along with a pre-experimental online survey and a post-experimental online survey was used to identify students' perception of OTC codeine, the impact of information design on eye-movement, and effective ways of displaying warning terms. Two samples with similar word count, template, and efficacy but with different ways of displaying warnings were chosen for the eye-tracking experiment. Thus, the independent variables are the displayed location of warning information and appeared frequency of occurrence, and the dependent variables are participants' reaction time and accuracy of finding several specific warning terms and attention locations. One sample was expected to establish a feasible standard for warning design, based on the understanding of information design principles [40–43]. We hypothesized that frequently appeared and highlighted information is more accessible for readers to recognize. With a systematic analysis of the research data and findings, this paper will conclude with answers to three research aims and the hypothesis proposed in the sample selection.

2. Materials and Methods

Three experimental methods were adopted. Two rounds of case studies on OTC codeine-containing medicines that are on sale were conducted to develop a better understanding of existing warning designs of addiction on the PILs. An eye-tracking experiment, which measures readers' horizontal gaze nystagmus, was conducted to study how the information affects mental functioning. Finally, surveys about personal information and the perception of OTC codeine was conducted before and after the eye-tracking experiment.

2.1. Case Study

In the first round of case studies, PILs of 46 OTC medicines available in England were collected in hard copies from 16 English volunteer students at the University of Leeds. Among the PILS collected, 16 were PILs of OTC analgesics. Five of OTC analgesics contained codeine as one of the active ingredients, namely, Syndol Tables from SANOFI, Solpadeine Plus from Omega Pharma Ltd., Paramol Tablets from Reckitt Benckiser Healthcare Ltd., Co-damol Tablets from Accord, and Co-damol Effervescent Tablets from Zentiva.

Then, in the second round of case studies, more PILs of OTC codeine-containing medicines were collected online through the electronic medicines compendium (EMC), which is a website that offers more than 14,000 documents of medicines licensed for use in England [44]. The other 14 active PILs of codeine-containing medicines were found. The PILs would be investigated in terms of target symptoms, word count, structural layout, and placement of warning signs of addiction.

2.2. Eye-Tracking Experiment and Survey

2.2.1. Sample Selection

For the eye-tracking experiment, two samples with different places and ways to display warning signs were selected from PILs of OTC codeine collected in the case studies. Based on our understanding of information design principles, one was expected to establish a feasible standard of information placement in comparison to another sample. In order to minimize the variance from wording and template, the selected samples were similar in word count, text column number, and efficacy. In accordance with these criteria, two PILs with a two-column layout, the PILs of Solpadeine Plus from Omega pharma Ltd. and Codeine Phosphate from Thronton & rose Ltd., were selected as Sample 1 and Sample 2, respectively. Based on information design principles [40–43], we hypothesized that the more frequently the information is mentioned, the more accessible the information is to find, and the terms highlighted in color or icons are more legible than using bolded words, followed by bolded sentences and then non-bolded sentences. Therefore, Sample 1 was assumed to establish a feasible standard for the way of displaying warning signs of addiction. Meanwhile, Solpadine Plus was also identified as the most common licensed OTC codeine in Europe [45].

2.2.2. Questions in the Experiment

A pre-experimental survey was used to collect the user's personal information and perception toward OTC codeine. Besides closed questions about age, gender, nationality, and the hometown of participants, two open-ended questions were designed to investigate participants' perception of codeine-containing medicines.

Then, six tasks were taken by participants at the beginning of the eye-tracking experiment. Participants were asked to find task-related information on the leaflets. The first three questions required them to find information on target symptoms, dosage, and side-effects of the medicine, which were proven to be the most prominent information of a PIL [46]. The next three questions asked participants to identify why the medicine is only for a short-time use, the signs of addiction, and the frequency of mentioning the warning sign of addiction in the sample.

At last, a questionnaire for the follow-up survey was created to identify participants' attitudes toward OTC codeine-containing medicines, and their perception of design. There were four open-ended questions and one question was asked twice, both at the beginning and the end of the experiment. In total, 16 questions were used throughout the experiment, which are summarized in Table 1.

Table 1. Questions asked before, during, and after the eye-tracking experiment.

Questions asked	d before the eye-tracking experiment:			
Question 1:	estion 1: How old are you?			
Question 2:	Which gender do you identify yourself as?			
Question 3:	What is your nationality?			
Question 4:	Where is your home town?			
Question 5:	Are you familiar with opioid analgesic or codeine-containing medicines?			
Question 6:	In what situation do you tend to buy over-the-counter codeine containing medicines?			
Questions asked	d during the eye-tracking experiment:			
Task 1:	Please identify what symptoms that this medicine is intended to treat.			
Task 2:	Please identify the maximum dosage for this medicine (dosage per day; maximum days).			
Task 3:	Please identify the side effects of this medicine.			
Task 4:	Please identify the reason why this medicine is only for short-time treatment.			
Task 5:	How do you know if you are addicted?			
Task 6:	Please identify how many times the warning sign of addiction was mentioned in this leaflet			
Questions asked	d after the eye-tracking experiment:			
Question 1:	In what situation do you tend to buy over-the-counter codeine containing medicines?			
Question 2:	How do you think of the availability and regulation of over-the-counter codeine?			
Question 3:	Have you seen these two patient information leaflets before?			
Question 4:	Which patient information leaflet is more helpful to you? Why?			

2.2.3. Participant Recruitment

In order to ensure similar cultural backgrounds and proficiency in English, we recruited 30 registered university students at the University of Leeds with English ethnicity and no specific restrictions on their major. The gender of the participants needed to be balanced since gender was relevant to substance abuse [47]. The participants were recruited online through an email written by the researcher and sent by the reception of the University of Leeds. This email contained the introduction of research background and objectives, the information of time and location, the target participants for the eye-tracking experiment and online surveys, and a link to a booking website (youcanbookme.com) which allowed the qualified participants to each select and book an experiment session online. In total, 30 qualified participants were recruited for the experiment. Participant recruitment and experiments took place from November to December 2019.

2.2.4. Testing Procedure

The experiment was conducted using an eye-tracking device to record each participant's eye movements for each sample. Researchers waited in the room ahead of the reserved session, with information sheets and consent forms prepared and printed out. As participants arrived, they were each introduced individually to the background, aim, and potential risks of the study through an information sheet and oral explanation by the researchers. The consent forms were then presented and signed before the commencing of the experiment.

For the implementation of the experiment, each participant was scheduled a maximum of one hour to finish a questionnaire, an eye-tracking experiment, and a follow-up survey. Once completing the pre-experimental survey, the eye-tracking experiment could be implemented. During the test, each participant was presented with the two samples in random order; that is, every 15 participants would be presented with samples in the same order. During the experiment, the participants were first given about 30 s to look at the sample before the tasks were introduced. Then the six different tasks of each sample were presented to the participants on the screen by order. They were asked to write down

answers to each task on paper. However, participants were not allowed to go back to check answers and were instructed not to go back to check answers or write down answers based on their knowledge. This process was conducted again for the sample presented in the second order.

After completing the eye-tracking experiment, a follow-up survey was displayed online using Google Forms. Participants were asked to complete the questionnaire by themselves. Intervention and assistance from the researcher were only given when questions or concerns were bought up by the participants. Each participant was given five English pounds at the end of their session as thanks for their time and contribution.

2.2.5. Data Collection and Analysis

The information collected from the case study was organized and analyzed by using SPSS (IBM, Armonk, NY, USA) statistics. As for the results of the eye-tracking experiment and online survey, all research data would be retained in the digital format. The results of the eye-tracking experiment were displayed in heat maps; the influence of information design on the effectiveness of the PIL would be measured based on the overlap of the correct answer and color-coded areas, the color-coded areas that did not contain the correct answer, and the sum of time to find information for all the tasks.

2.2.6. Ethical Consideration

This research complied with the American Psychological Association Code of Ethics and was approved by the Institutional Review Board at the University of Leeds (LTDESN-116).

3. Results

3.1. Case Study

Five out of 46 PILs collected in the first round of case studies were codeine-containing medicines. They were offered by five different volunteers. Then, 14 leaflets of codeine-containing medicines (with 10 for pain relief, three for dry cough, and one for cold & flu) were found on the EMC by researching the keyword, "codeine," within the category of OTC medicines. Therefore, 19 PILs of codeine-containing OTC medicines were found for further investigation. As shown in Table 2, the 19 PILs were grouped by efficacy and listed in alphabetic order. They were each analyzed in terms of text layout, word count, visual elements, and print size. As seen in Table 2, 78% of codeine-containing medicines were designed to treat pain. The content of codeine per pack varies with the name of medicines and pack size available on the market. As for the design of the PILs, 68% of medicines were designed with a two-column structure layout, and the warnings about addiction were not colored or did not accompany an icon in 63% of the PILs.

No	Medicine	Efficacy	Text Column	Word Count	Icons & Colour	Print Size/cm
1	Co-damol Tablets (Accord)	Pain	2	1659	None	21.0×29.6
2	Co-damol Tablets (M&A Pharmachem Ltd.)	Pain	2	2189	None	12.4×20.7
3	Co-damol Effervescent Tablets (Zentiva)	Pain	1	3020	None	20.9×50.0
4	Codeine Phosphate (Thornton & rose Ltd.)	Pain	2	2068	None	21.0×29.7
5	Codis 500 (Reckitt Benckiser Healthcare UK Ltd.)	Pain	2	1788	None	24.1×48.2
6	Migraleve Film-coated Tablets (McNeil Products)	Pain	3	2478	Both	25.0×14.5
7	Nurofen Plus (Reckitt Benckiser Healthcare Ltd.)	Pain	2	4914	None	19.2×29.6
8	Panadol Ultra Tablets (GlaxoSmithKline Healthcare)	Pain	2	2152	Icon	14.1×10.6
9	Paramol Tablets (Reckitt Benckiser Healthcare Ltd.)	Pain	2	1839	None	18.0×26.7
10	Paracetamol, Codeine & Caffeine (Fannin Limited)	Pain	2	1717	None	29.7×23.8
11	Paracodol Tablets (Delpharm Gaillard)	Pain	2	1468	Icon	15.0×25.0
12	Solpadeine Plus (Omega pharma Ltd.)	Pain	2	1936	Icon	15.0×30.5
13	Syndol Headache Relief Tablets (SANOFI)	Pain	2	1894	None	21.0×28.0
14	Syndol Film-Coated Tablets (SANOFI)	Pain	2	2897	None	19.0×29.7
15	Veganin (Omega Pharma Ltd.)	Pain	2	2482	Colour	14.0×22.9
16	Pulmo Bally (DDD Limited)	Cold & flu	3	1048	None	16.5×12.0
17	Codeine Linctus (Thronton & rose Ltd.)	Dry cough	3	1196	Icon	17.0×6.49
18	Codeine Linctus BP (Pinewood Laboratories Ltd.)	Dry cough	1	1320	None	21.0×29.7
19	Galcodine Linctus (Thronton & Ross Ltd.)	Dry cough	4	1300	Icon	21.0×29.7

Table 2. Analysis of the patient information leaflets (PILs) of over-the-counter (OTC) codeine containing medicines collected for case studies.

The ways to present a warning about addiction were investigated in detail. Four ways of displaying warnings about addiction were identified in four sections of the PILs. In Table 3, with the use of a heat map, four kinds of warning signs were presented in four different colors and were distributed in four rows, each row symbolizing a section of information on the PIL. As seen from Table 3, the warning terms and signs of addiction were presented in all codeine-containing analgesics, either highlighted or unhighlighted. However, for medicines targeting on cold and flu and dry cough, only one of them contained a warning about addiction.




Table 3. Investigating the presentation for warnings of addiction.

Based on the criteria for sample selection discussed earlier in the Section 2.2.1., two PILs with similar layout, word count, and efficacy but with a different way of displaying warnings about codeine were selected for further testing. As seen from Tables 2 and 3, leaflet number 4 and 12 shared similar layout, word count, and efficacy, but most different way of displaying warnings of addiction. Therefore, the PILs of Solpadeine Plus from Omega pharma Ltd. and Codeine Phosphate from Thornton & rose Ltd. were selected as Sample 1 (Figure 1) and Sample 2 (Figure 2) [48,49], respectively.



Figure 1. Sample 1 [48].

ATIENT INFORMATION LEAFLET	 Has previously had an addiction to medicines containing codeline or morphine. 	Driving and using machinery	4. Possible side effects
hornton & Ross Codeine Phosphate 5mg/5ml Oral Solution	Talk to your doctor or pharmacist if the patient has any of	This medicine may affect your ability to drive or operate machinery. If you are feeling dizzy or drowsy , do not drive or operate machinery.	Like all medicines, Codeine Phosphate Oral Solution can cause side effects, although not everybody gets them.
Sing/Sint Of an Solution	the following: Intelerance to some sugars.	The medicine can affect your ability to drive as it may make you sleepy or dizzy.	Important side effects
ead all this leaflet carefully before you	 Kidney or liver problems (a reduced dose may be recommended by 	 Do not drive while taking this medicine until you know how it affects 	If you think that you have any of the following side effects or
art taking this medicine.	 your doctor). A history of asthma or other breathing problems, including bronchitis. 	 You. It is an offence to drive if this medicine affects your ability to drive. 	symptoms, stop using this medicine immediately and see a doctor as scon as possible.
This medicine has been prescribed for you personally and you should	 Low blood pressure. 	 However, you would not be committing an offence if: 	 Allergic reactions including skin rashes, itching and blistering.
not pass it on to others. It may harm them, even if their symptoms are the same as yours.	 Irritable bowel syndrome (IBS) or other bowel problems. Abdominal pain. 	 The medicine has been prescribed to treat a medical or dental problem and 	Other possible side effects are:
Keep this leaflet. You may need to read it again.	 Myasthenia gravis (a disease of the muscles). 	 You have taken it according to the instructions given by the prescriber or in the information maxield with the medicine and 	Hallucinations, mood changes, feeling restless or confused.
If you have further questions, please ask your doctor or pharmacist. If any of the side effects become serious, or if you notice any side	 Underactive thyroid or adrenal gland problems (a reduced dose may be recommended by your doctor). Gallstones or bit doct problems. 	 It was not affecting your ability to drive safely. 	 Dizziness or vertigo, feeling unwell, drowsiness, disturbed sleep, headache or seizures.
effects not listed in this leaflet, please tell your doctor or pharmacist.	 Prostate problems. 	Talk to your doctor or pharmacist if you are not sure whether it is safe	 Pimpoint pupils or other problems with eyesight. Abnormal heartbeat.
in this leaflet	Problems passing urine. Improve heartheartheartheartheartheartheartheart	for you to drive while taking this medicine.	· Feeling faint when standing up low body heat facial flushing or fluid
. What is the medicine and what does it do?	 A history of epilepsy or fits. 	Important information about some of the ingredients of this	retention (e.g. swollen and/es and foet). • Slow, shallow breathing.
 Before you take the medicine. How to take the medicine. 	 Or is suffering from shock. 	medicine.	 Slow, shallow treatning. Feeling or being sick, constipation, abdominal pain (including pain
 Possible side effects 	Codeine is transformed to morphine in the liver by an enzyme. Morphine is the substance that produces pain relief.	 This medicine contains sucrose and ethanol (alcohol) as ingredients. If you have been told by your doctor that you have an intolerance to 	caused by inflammation of the pancreas (pancreatitis) or bile duct
5. How to store the medicine 6. Further information	Some people have a variation of this enzyme and this can affect	some sugars, confact your doctor before taking this medicinal product.	problems (biliary spasm)), loss of appetite or dry mouth. • Sweating, muscle twitching or muscle stiffness.
 canno anycod000 	people in different ways. In some people, morphine is not produced or produced in very small quantities, and it will not provide enough	 It contains 4.25g sucrose per 5ml spoonful. This should be taken into 	· Ureteric spasm (urine tube problem causing abdominal or lower back
1. What is the medicine and	pain relief. Other people are more likely to get serious side effocts	account in patients with diabetes mellitus. • This medicinal product contains 2.1 vol% ethanol (alcohol), i.e. up	pain), difficulty in passing urine. • Low sexual urge.
what is the medicine and what does it do?	because a very high amount of morphine is produced. If you notice any of the following side effects, you must stop taking this medicine and	to 166mg per dose, equivalent to 4.2ml beer, 1.75ml wine per dose.	· Taking a painkiller for headaches too often or for too long can make
The name of your medicine is Thornton & Ross Codeine Phosphate	seek immediate medical advice: slow or shallow breathing, confusion,	Harmful for those suffering from alsoholism.	diem worse.
25mg/5ml Oral Solution, which will be referred to as 'Codeine	sleepiness, small pupils, feeling or being sick, constipation, lack of appetite.	To be taken into account in pregnant or breast feeding women, children and high-risk groups such as patients with liver disease, or	Taking codeine regularly for a long time can:
Phosphate Oral Solution' throughout this leaflet. This product contains codeine. Codeine belongs to a group of medicines called opioid.		epilepsy.	 Lead to addiction, or dependence, which might cause you to feel restless and irritable when you stop taking the syrup, or tolerance
nalgesics which act to relieve pain. It can be used on its own or in	Use in children and adolescents after surgery Codeine should not be used for rain relief in children and adolescents	 Do not take this medicine if suffering from alcoholism or 	(the medicine loses its effect).
combination with other painkillers such as paracetamol.	after removal of their tonsils or adenoids due to Obstructive Sleep	dependence on other opiates. • It also contains sodium hydroxybenzoates which may cause allergic	 Make Irritable Bowel Syndrome worse.
What is it for?	Apnoea Syndrome.	reactions (possibly delayed).	If any of the side effects become serious or if you notice any other
Codeine Phosphate Oral Solution can be used in two ways:	Use in children with breathing problems		effects not mentioned here, tell your doctor or pharmacist straight away. They will advise you what to do.
In adults and children over 12 years of age for the short-term relief of moderate pain that is not relieved by other painkillers such as	Codeine is not recommended in children with breathing problems, since	3. How to take the medicine	
paracetamol or iburrofen alcne.	the symptoms of morphine toxicity may be worse in these children.	This medicine has been prescribed for you personally. Do not pass it on to others as it may harm them.	Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or muse.
 For the relief of the symptoms of diarthoes in adults and children more 12 years. 	Talk to your doctor or pharmacist if the patient is already		This includes any possible side effects not listed in this leaflet.
010 12 9003	taking any of the following: • Metoelopramide or domperidone (anti-nausea and vomiting	Dose: Always take your modicine as prescribed by your doctor. The doctor may sometimes prescribe different doses to those	You can also report side effects directly via the Yellow Card Scheme at
2. Before you take the medicine	molicines)	listed below. Always follow the doctor's instructions carefully.	www.mhra.gov.uk/yelloweard or search for "MHRA Yellow Card" in the Google Play or Apple App Store.
Take special care with codeine	 Flocainide or mexiletine (for the treatment of irregular heartbeat). Any tranquillisers, antidepressants, sedatives or sleeping tablets. 	The usual dose for the relief of pain is:	By reporting side effects you can help provide more information on the
 Do not take for longer than directed by your doctor. 	 Any tranquinisers, antidepressants, senarives or steeping tattets. Any medicine used in the treatment of severe mental illness. 	Adults and Children over 12 years: 1 or 2 x 5ml speenfuls by mouth	safety of this medicine.
 In tare cases people can be at increased risk of developing 	Concomitant use of this product and sedative medicines such as	every 6 hours as needed. Do not take more than 8 x 5ml spoonfuls in	5. How to store the medicine
overdose symptoms from codeine even when they have taken the recommended dose (people who are "ultra-rapid metabolisers" of	benzodiazepines or related drugs increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-	any 24 hours. This medicine should not be taken for more than 3 days. If the pain does	
codeine). If you experience severe effects including feding sick,	threatening. Because of this, concomitant use should only be considered	not improve after 3 days, talk to your doctor for advice.	Keep out of the sight and reach of children. Do not use the medicine after any expiry date, which may appear on the
being sick, constipation, lack of appetite, feeling tired, sleeping longer than normal, shallow or slow breathing, then stop taking this	when other treatment options are not possible. However if your doctor does prescribe this product together with	Codeine Phosphare Oral Solution should not be taken by children below the age of 12 years, due to the risk of severe breathing problems.	label.
medicine and seek immediate medical advice.	sedative medicines the dose and duration of concomitant treatment	Elderly, frail, weak or infirm: The doctor will prescribe the correct	Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to your plurmacist. These measures
 Taking codeine regularly for a long time can lead to addiction, which might cause you to feel restless and irritable when you stop. 	should be limited by your doctor. Please tell your doctor about all sedative medicines you are taking, and	dose for you.	will help protect the environment.
 Taking a painkiller for headaches too often or for too long can make 	follow your doctor's dose recommendation closely. It could be helpful	The usual dose for diarrhoea is:	
them worse. If you are aldedy use with caution as the medicine can cause	to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms.	Adults and children over 12 years: 1 or 2 x 5ml speonfuls by mouth	6. Further information
incontinence, diarrhoea, stomach pain and occasionally a blocked	Pregnancy and breast feeding	every 6 hours as needed. Do not take more than 8 x 5ml spoontfals in any 24 hours.	What the medicine contains The active substance is codeine phosphate 25mg per 5ml.
bowel.	Codeine Phosphate Oral Solution should not be used in pregnancy	This medicine should not be taken for more than 3 days. If the diarrhoea	The other ingredients are sodium methyl hydroxybenzoate (E219),
Do not take the medicine if the patient: Is allergic to codeine or any of the ineredients listed.	unless the doctor has told you to do so.	does not improve after 3 days, talk to your doctor for advice. Codeine Phosehate Oral Solution should not be taken by children below	ethanol, purified water and syrup (contains sucrose).
Has liver disease, severe kidney problems, a head injury.	Use in late pregnancy may cause shallow breathing in the newborn baby and problems for the mother during labour.	the age of 12 years, due to the risk of severe breathing problems.	What the medicine looks like
persistent headache, or raised head pressure. Is having an asthma attack or has general shortage of breath.	Do not take codeine while you are breast feeding. Codeine and	Elderly, frail, weak or infirm: The doctor will prescribe the correct dose for you.	The medicine is an almost colourless syrupy liquid.
Is under 12 years.	morphine passes into breast milk.		Marketing Authorisation Holder and Manufacturer Thomton and Ross Ltd., Huddersfield.
 Has problems emptying the bowel or has other problems associated with the bowel or intestine. 		If you take too much see a doctor straight away.	HD7 5QH, England.
 Suffers from alcoholism. Do not take the medicine for pain relief in children and adolescents 		If you accidentally miss a dose, take the normal dose as soon as you remember and then continue to take the medicine in the way you have	This leaflet was last revised in
(0-18 years of age) after removal of their tonsils or adenoids due to		been told. Do not double up on the dose to make up for missed	August 2018
obstructive sleep apnoea syndrome.		doses.	PL 00240/s2138
 If you know that you metabolise very rapidly code into morphine. 	Turn over ₽		PL 00240/0213K
If you are breastfeeding.	92767561808		92767561808

Figure 2. Sample 2 [49].

3.2. Eye-Tracking Experiment

3.2.1. Participants' Information and Their Perception of OTC Codeine

Among the 30 participants of the eye-tracking experiment, 15 were female and 15 were male. Twenty-three participants were between the age of 20–30, the other seven were 30–40. All the recruited participants were English nationals, and five of them mentioned they were immigrants to England. English was the first language of 25 participants. The results for participants' familiarity and attitudes toward OTC codeine are summarized in Figure 3. Twenty-seven percent of them tend to purchase codeine-containing medicines when feeling sick and merely 3% chose never to purchase it. Eighty percent of them were unfamiliar with codeine.




Figure 3. The results of two questions from the pre-experimental survey: (**a**) Are you familiar with opioid analgesic or codeine-containing medicines? (**b**) Please identify how many times the warning sign of addiction was mentioned in this leaflet.

3.2.2. Testing Results

For the eye-tracking experiment of two previously selected samples, the six tasks of each sample were introduced to each participant during the experiment. The results of the eye-tracking experiment were summarized in Figures 4–6 using heat-maps. Figures 4–6 presented participants' initial focus of the sample, the eye movement, and the coverage of eyesight throughout the whole experiment, respectively. The field of view was colored in the heat-map. The warmer the color gets, the better the attention was gained in the section. The correct answers for each task are boxed in the figures.

As shown in Figure 4, information placed on the upper left corner of a PIL was most likely to be observed in the first 30 s of glances.

Intital glance over



Figure 4. The result of the eye-tracking experiment for the first 30 s (shown by heat-map images); the warmer the color gets, the more the attention was gained in the section. (**a**) The field of view while looking at sample 1; (**b**) sample 1; (**c**) the fields of view while looking at sample 2; (**d**) sample 2.

Participants' eye movements while doing six tasks are presented in Figure 5. For the first three tasks, participants tended to rely on the headline section, especially when there was a headline section that contained a summary of the information. Then for the fourth question on the reasons for short-time treatment, readers of Sample 1 were capable of finding the answers in two sections. The majority of them primarily found the information under the sub-heading, "warning and precaution" in bold font, while others found the information in the headline section. For Sample 2, even though the readers eventually found the information, the majority of them skimmed all over the places to seek information. In task 5, the signs of addiction were asked. This information was displayed twice in Sample 1 and once in Sample 2, respectively. Nearly all readers of Sample 1 identified the information in the sub-section called "How do I know if I am addicted?", which was highlighted and labelled with an icon. For that of Sample 2, when the information was hidden in the "possible side effect" section, it seemed that the participants lost focus. For task 6 which asked about the frequency of displaying warnings about addiction in each sample, the result indicated that readers were capable of finding the warnings on multiple sections of Sample 1, while only one warning was found in Sample 2 by the majority of participants.

Task 1:Please identify what symptoms is this medicine intended to treat.

Task T:Please Identify what s	ymptoms is this medicine intende	ed to treat.	
And a second sec		And an analysis Analysis Analysis Analysis Analysis Analysis Analysis	
Task 2:Please identify the ma	aximum dosage for this medicine	(dosage per day; maximum days).	
		Statistical S	
Task 3: Please identify the	side effects of this medicine.		
		Statistical Statistice Statis Statistical Statistical Statistical Statistical Statist	An observations of the second
Task 4: Please identify the	reason why this medicine is	only for short time treatment.	
		Normalization An and a state of the sta	
Task 5: How do you know	if you are addicted?		
		Standardsminu Stan	
Task 6: Please identify how	w many times the warning sig	n of addiction was mentioned in thi	s leaflet.
		Standarding Standarding Standarding <td></td>	

Figure 5. Field of view: the result of the eye-tracking experiment (shown by heat-map images); the left side is Sample 1 and the right side is Sample 2. The correct answers for each task are boxed in the figures.

For the field of view presented in Figure 6, the intense color occupied 4.68% and 7.85% of the area in Sample 1 and Sample 2, respectively. Among the intensely colored area, 38.5% of the area in Sample 1 and 57.5% of the area on Sample 2 remained unboxed, which means the readers of Sample 2 spent more time on ineffective information than those of Sample 1.

Field of view through out the experiment.



Figure 6. Field of view for all six tasks, the left side is sample 1 and the right side is sample 2. The correct answers for each task are boxed in the figures.

Then, the total time used by each participant to find correct answers to the tasks was measured and summarized in Figure 7. The average time spent on Sample 1 was 9.1 min, and that on Sample 2 was 10.9 min. The *p*-value was calculated as 0.029. Therefore, information design could influence readers' speed of finding information. In general, participants found information more quickly using Sample 1 than using Sample 2.




Figure 7. The time for each participant to find answers for all tasks by using different samples. Only four participants which are marked by a black box spent a longer time on sample 1 than sample 2.

3.3. Interview

As shown in Figure 8, after being informed with the addictive risk of OTC codeine, 27% of participants said they would never buy codeine-containing medicines; 55% of participants were likely to purchase OTC codeine-containing medicines in the future, and six percent of them would only consume codeine-containing medicine if it was prescribed. For the availability and regulation of OTC codeine, 28% of the participants were unfamiliar with the regulation and danger; 47% participants argued that there should be tight restrictions on the regulation and availability since it had the potential for addiction, and 25% of them found that regulation and availability of OTC codeine was appropriate enough. None of the participants had seen Sample 1 and 2 before the eye-tracking experiment. Their preference for both samples was summarized in Table 4.




Figure 8. The results of two questions from a follow-up survey. From the left to the right: (**a**) In what situation do you tend to buy codeine-containing medicines? (**b**) How do you think of the availability and regulation of codeine? (**c**) Have you seen these two patient information leaflets before?

For participants' preference of sample PILs summarized in Table 4, Sample 1 and 2 were both favored by 50% of readers. However, the feedback from the participants indicated that Sample 2 was mostly favored for its overall layout, while Sample 1 was preferred for its clear heading, summarization of information in the headline section, and clear and repeated warning on addiction.

	Frequency	Feedbacks	Frequency
Sample 1		I felt that I could find things easier in sample 1	2
		Clear layout, clear heading, clear warning, summarized the important information at the top of the sheet.	4
		Easier to find the issue as they had a bold format. Address issues more.	2
		The structure of the pamphlet, notable the subheadings and bullet points.	1
	15	All the primary information was right at the start of the leaflet which you immediately go toward. The other one you have to hunt for the information.	1
		Clear to read, and the font was larger. It is easy to find what you needed with subheading in comparison to the second.	2
		It was clearer in pointing out the addictive property of codeine, which is very important and the information was grouped together well within the subtitles.	1
		Sample 1 had more information about addiction, and it was clearly laid out.	2
		The categories are divided better into sections.	1
Sample 2		The layout and typeface are more legible than Sample 1.	8
		It was easier to read. Sample 1 had too much bold lettering.	1
	15	This one is easier to read. The information on Sample 1 is all over the place.	1
		The headings are more descriptive of each section.	2
		It has more subheadings than Sample 1.	1
		Sample 1 had too much information; the font size is too small to read.	1

Table 4. Answers to the question "Which PIL is more helpful to you?".

4. Discussion

With a particular focus on English university students, this research aimed to explore the effect of information design on readers' eye movement, ability to identify a legible warning design for the PIL, and to investigate university students' perception of OTC codeine. Responding to the first research aim, the result proved that different ways and places of displaying a warning about addiction on the PIL significantly affected readers' eye movement. Legible warning designs could speed up the time readers spent searching for information, thus promoting patient education and reducing unintentional medicine misuse [30,39,50,51]. For the hypothesis about warning design made prior to the experiment, the results showed that university students tend to read from the upper left and identify risk factors in the "possible side effect (PSE)" section, but minor differences were identified on how different formats of the highlight influenced their eye movement. Therefore, the proposed hypothesis was only partially

correct. For the second research aim based on the research results, it is suggested that in order to achieve effective communication of warning, two distinctively highlighted warning terms should be displayed in both the headline section and the "possible side effect" section, and the warning signs of addiction should be placed in a separate sub-section under the "possible side effect" section. Then for the last research aim, which was about students' perception of OTC codeine, a majority of English university students were unfamiliar with the risk of codeine. After acknowledging the risks of codeine through reading the PILs, 47% of them suggested tight regulations on OTC codeine, and 55% of them may purchase it in the future.

With the influence of information design to the effective communication of information being approved [38,46,52], findings of this research added credit to previous researches by using results of the eye-tracking experiment to present English university students' ways of reading information on the PIL. Since information design was necessary for patient education [30], the effective presentations of warning about addiction were aimed to be identified in this research. For the navigation method, the result suggested that most readers tend to start reading the information from the upper-left corner. This finding proved the usefulness of the headline section; however, this result contradicted that of Dolk et al. [53]. When the information process model was identified by Lonsdale [54], the result suggested that people are more likely to scan (read the information thoroughly from up to down and left to right) the PILs that have a headline section which contained a summary of relevant information and skim (purposefully search for content) the PILs which were without such section. For the risk-related information, participants were more likely to search within the headline section that contained a summary of relevant information, and the "possible side effect" section. Therefore, the term, "Can cause addiction. For three days use only" displayed clearly both at the upper-left corner and in the "possible side effect" section of a PIL is the minimum requirement of the effective communication. For the signs of addiction, the result suggested that the best practice was to include the information in a highlighted sub-section under the "possible side effect" section. This finding is meaningful since the easiness to read is relevant to patient education and users' willingness to read [55]. However, if this is used as the standard, then only 21% of collected PILs of OTC codeine met the criterion.

Apart from the results of the eye-tracking experiment, changes in students' perception toward codeine also indicated the significance of a legible PIL. According to the findings, students became more conservative about codeine consumption because of education about codeine, as the rejection rate on codeine consumption raised from three percent to 27%. In total, 80% of participants were unfamiliar with codeine, demonstrating the importance of the warnings about addiction for patient education, especially for first-time users [13]. However, relevant warnings were not found in 15.7% of the recruited PILs of OTC codeine, especially for those not aimed at treating pain. This finding can be worrying since codeine was found in PILs of OTC analgesics offered by 31.3% of volunteers. Current regulations on warning signs of codeine-containing medicines are also actionable for OTC codeine-containing analgesics. Similar regulations may be applied to OTC codeine that treats other symptoms, such as dry cough, cold, and flu. Besides, another worrying finding was that half of the participants retained the possibility to consume OTC codeine in the future even though they were informed of the risk of codeine. This could be the reason for banning OTC opioids, which was suggested in previous studies and implemented in Australia in 2018 [56,57].

Limitations

It should be acknowledged that this study was limited in several aspects. Firstly, the result could be potentially limited by the sampling strategy since the participants were only recruited within the University of Leeds. Secondly, the effect of the recommended ways of presenting the information could be influenced by multiple factors once it is applied in practice, such as literacy levels, co-morbidities, familiarity levels, and different design elements used in each PIL [58–62]. Thirdly, while this study only discussed the way of displaying warnings on the PIL with a two-column layout for health students, it might be essential to further prove the suggested way of displaying warning terms again by focusing

on the PILs with a different design. Lastly, since better pain relief is one of the reasons for medication misuse [5], conducting the experiment again by testing patients who might benefit from OTC codeine could be another way to further verify the results.

5. Conclusions

In order to prevent OTC codeine misuse, this research proposed a more specified way to present warnings of addiction. It is suggested that there should be at least two highlighted terms, "Can cause addiction. For three days use only," displaying separately in the headline section and "possible side effect" section of a PIL. The warning signs of addiction should be placed outstandingly as a sub-section within the section of "possible side effects." Better patient education is meaningful for English university students since most of them are unfamiliar with codeine, which would help reduce the chances of unintentional codeine misuse.

Author Contributions: Conceptualization, J.Z., T.H.; methodology, Y.C.; validation, T.H., J.Z., Y.C. and S.W.; formal analysis, T.H.; investigation, J.Z.; resources, J.Z.; writing—original draft preparation, J.Z. and Y.C.; writing—review and editing, T.H., J.Z., Y.C. and S.W.; project administration, T.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by National Social Science Fund, grant number 18BRK009.

Acknowledgments: Appreciations are given to all students who offered sample PILs voluntarily and the ones who attended and contributed to the eye-tracking experiment.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Vorvivk, L. *Over-the-Counter Medicines: MedlinePlus Medical Encyclopedia;* American Accreditation HealthCare Commission: Bethesda, MD, USA, 2019. Available online: https://medlineplus.gov/ency/article/002208.html (accessed on 20 October 2019).
- Medicines and Healthcare Products Regulatory Agency. Over-the-Counter Painkillers Containing Codeine or Dihydrocodeine; Medicines and Healthcare Products Regulatory Agency: London, UK, 2014. Available online: Gov.uk.https://www.gov.uk/drug-safety-update/over-the-counter-painkillers-containing-codeineor-dihydrocodeine (accessed on 20 October 2019).
- 3. Bond, C.M.; Bradley, C. Over the Counter Drugs: The interface between the community pharmacist and patients. *BMJ* **1996**, *312*, 758–760. [CrossRef]
- Blackwell, S.A.; Baugh, D.K.; Montgomery, M.A.; Ciborowski, G.M.; Waldron, C.J.; Riley, G.F. Noncompliance in the Use of Cardiovascular Medications in the Medicare Part D Population. *Medicare Medicaid Res. Rev.* 2011, 1. [CrossRef] [PubMed]
- 5. Cooper, R.J. Surveillance and uncertainty: Community pharmacy responses to over the counter medicine abuse. *Health Soc. Care Community* **2013**, *21*, 254–262. [CrossRef] [PubMed]
- 6. Fingleton, N.A.; Watson, M.C.; Duncan, E.; Matheson, C. Non-prescription medicine misuse, abuse and dependence: A cross-sectional survey of the UK general population. *J. Public Health* **2016**, *38*, 722–730. [CrossRef]
- Foley, M.; Carney, T.; Rich, E.; Parry, C.; Van Hout, M.-C.; DeLuca, P. Medical professionals' perspectives on prescribed and over-the-counter medicines containing codeine: A cross-sectional study. *BMJ Open* 2016, 6, 011725. [CrossRef]
- 8. Cooper, R.J. 'I can't be an addict. I am.' Over-the-counter medicine abuse: A qualitative study. *BMJ Open* **2013**, *3*, e002913. [CrossRef] [PubMed]
- 9. Orriols, L.; Gaillard, J.; Lapeyre-Mestre, M.; Roussin, A.; Roussin, P.A. Evaluation of Abuse and Dependence on Drugs Used for Self-Medication. *Drug Saf.* **2009**, *32*, 859–873. [CrossRef]
- 10. nhs.uk. Codeine: Medicine to Treat Pain and Behavior. Also, a Cough Syrup. Nhs, 2019. Available online: https://www.nhs.uk/medicines/codeine/ (accessed on 20 October 2019).
- 11. Bunn, R.; Gregory, A. P113 Re-designing how patient medicines information is presented on discharge. *BMJ Support. Palliat. Care* **2013**, *3*, A50. [CrossRef]
- 12. Toms, L.; Derry, S.; Moore, R.A.; McQuay, H.J. Single dose oral paracetamol (acetaminophen) with codeine for postoperative pain in adults. *Cochrane Database Syst. Rev.* **2009**, 2009, 001547. [CrossRef]

- 13. Chou, R. 2009 Clinical Guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain: What are the key messages for clinical practice? *Pol. Arch. Intern. Med.* **2009**, *119*, 469–477. [CrossRef]
- Van Hout, M.-C.; Norman, I.; Information, P.E.K.F.C. Misuse of non-prescription codeine containing products: Recommendations for detection and reduction of risk in community pharmacies. *Int. J. Drug Policy* 2016, 27, 17–22. [CrossRef] [PubMed]
- 15. Department of Health. Drug Misuse and Dependence. UK Guidelines on Clinical Management: Department of Health. 2017. Available online: https://assets.Publishing.Service.Gov.uk/government/uploads/system/uploads/attachment_data/file/673978/clinical_guidelines_2017 (accessed on 20 October 2019).
- Kinnaird, E.; Kimergård, A.; Jennings, S.; Drummond, C.; DeLuca, P. From pain treatment to opioid dependence: A qualitative study of the environmental influence on codeine use in UK adults. *BMJ Open* 2019, 9, e025331. [CrossRef] [PubMed]
- 17. Mort, J.R.; Ndehi, L.N.; Stacy, J.N.; Mort, P.J.R.; Shiyanbola, O.O.; Xu, Y. Opioid-Paracetamol Prescription Patterns and Liver Dysfunction. *Drug Saf.* **2011**, *34*, 1079–1088. [CrossRef] [PubMed]
- 18. Ford, C.; Good, B. Over the counter drugs can be highly addictive. *BMJ* **2007**, *334*, 917–918. [CrossRef] [PubMed]
- 19. Kimergård, A.; Foley, M.; Davey, Z.; Dunne, J.; Drummond, C.; Deluca, P. Codeine use, dependence and help-seeking behavior in the UK and Ireland: An online crosssectional survey. *QJM* **2017**, *110*, 559–664. [CrossRef]
- Muhuri, P.K.; Gfroerer, J.C.; Davies, M.C. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States; Substance Abuse and Mental Health Services Administration: Center for Behavioral Health Statistics and Quality: Rockville, MD, USA, 2013. Available online: http://www.samhsa.gov/data/ (accessed on 20 October 2019).
- 21. Mill, D.; Johnson, J.; Cock, V.; Monaghan, E.; Hotham, E.D. Counting the cost of over-the-counter codeine containing analgesic misuse: A retrospective review of hospital admissions over a 5 year period. *Drug Alcohol Rev.* **2017**, *37*, 247–256. [CrossRef]
- 22. Gillespie, N.A.; Bates, T.C.; Hickie, I.B.; Medland, S.E.; Verhulst, B.; Kirkpatrick, R.M.; Kendler, K.S.; Martin, N.G.; Benotsch, E.G. Genetic and environmental risk factors in the non-medical use of over-the-counter or prescribed analgesics, and their relationship to major classes of licit and illicit substance use and misuse in a population-based sample of young adult twins. *Addiction* **2019**, *114*, 2229–2240. [CrossRef]
- International Narcotics Control Board. Report of the International Narcotics Control Board for 2017; International Narcotics Control Board: Vienna, Austria, 2017; Available online: https://www.incb.org/documents/ Publications/AnnualReports/AR2017/Annual_Report/E_2017_AR_ebook.pdf (accessed on 20 October 2019).
- 24. McCabe, S.E.; Teter, C.J.; Boyd, C.J.; Wilens, T.E.; Schepis, T.S. Sources of Prescription Medication Misuse Among Young Adults in the United States: The Role of Educational Status. *J. Clin. Psychiatry* **2018**, *79*, 33–40. [CrossRef]
- Johnston, L.D.; O'Malley, P.M.; Bachman, J.G.; Schulenberg, J.E. Monitoring the Future: National Survey Results on Drug Use: 1975–2011: Volume II: College Students and Adults Ages; Institute for Social Research, The University of Michigan: Ann Arbor, MI, USA, 2012; pp. 19–50.
- 26. Bennett, T.H.; Holloway, K.R. Drug Misuse Among University Students in the UK: Implications for Prevention. *Subst. Use Misuse* **2013**, *49*, 448–455. [CrossRef] [PubMed]
- 27. Parry, C.D.H.; DeLuca, P.; Cooper, R.J.; Van Hout, M.-C. Do we have sufficient information to optimally inform regulatory or other policy decisions about medications containing codeine? *Addiction* **2015**, *110*, 1690–1691. [CrossRef] [PubMed]
- 28. Carayon, P. Human factors in patient safety as an innovation. *Appl. Ergon.* **2010**, *41*, 657–665. [CrossRef] [PubMed]
- 29. Van Hout, M.-C.; Hearne, E. Confessions of contemporary English opium-eaters: A netnographic study of consumer negotiation of over-the-counter morphine for misuse. *J. Subst. Use* **2014**, 1–12, 1–12. [CrossRef]
- 30. Tabor, P.A.; Lopez, D.A. Comply With Us: Improving Medication Adherence. J. Pharm. Pr. 2004, 17, 167–181. [CrossRef]
- 31. Harocopos, A.; Allen, B. Routes into Opioid Analgesic Misuse. J. Drug Issues 2015, 45, 385–395. [CrossRef]
- 32. McBride, A.J.; Pates, R.; Ramadan, R.; McGowan, C. Delphi survey of experts' opinions on strategies used by community pharmacists to reduce over-the-counter drug misuse. *Addiction* **2003**, *98*, 487–497. [CrossRef]

- 33. Young, A.; Smith, A.; Tordoff, J. What do patients' want? Time to innovate medicine information leaflets. *Int. J. Integr. Care* 2017, *17*, 15. [CrossRef]
- 34. Schmitz, J.; Kamping, S.; Wiegratz, J.; Müller, M.; Stork, J.; Colloca, L.; Flor, H.; Klinger, R. Impact of patient information leaflets on pain medication intake behavior. *PAIN Rep.* **2017**, *2*, e620. [CrossRef]
- 35. Ward, J.; Buckle, P.; Clarkson, P.J. Designing packaging to support the safe use of medicines at home. *Appl. Ergon.* **2010**, *41*, 682–694. [CrossRef] [PubMed]
- 36. Tobin, C.L.; Dobbin, M.; McAvoy, B. Regulatory responses to over-the-counter codeine analgesic misuse in Australia, New Zealand and the United Kingdom. *Aust. N. Z. J. Public Health* **2013**, *37*, 483–488. [CrossRef]
- Frei, M.Y.; Nielsen, S.; Dobbin, M.D.H.; Tobin, C.L. Serious morbidity associated with misuse of over-the-counter codeine–ibuprofen analgesics: A series of 27 cases. *Med. J. Aust.* 2010, 193, 294–296. [CrossRef]
- 38. Dickinson, D.; Teather, J.; Gallina, S.; Newsom-Davis, E. Medicine package leaflets—Does good design matter? *Inf. Design J.* 2010, *18*, 225–240. [CrossRef]
- 39. Patel, H.K.; Bapat, S.S.; Bhansali, A.H.; Sansgiry, S. Development of Prescription Drug Information Leaflets. *Ther. Innov. Regul. Sci.* **2017**, *52*, 118–129. [CrossRef] [PubMed]
- Raynor, D.K.; Dickinson, D. Key Principles to Guide Development of Consumer Medicine Information—Content Analysis of Information Design Texts. *Ann. Pharmacother.* 2009, 43, 700–706. [CrossRef] [PubMed]
- 41. Dowse, R.; Ehlers, M. Medicine labels incorporating pictograms: Do they influence understanding and adherence? *Patient Educ. Couns.* **2005**, *58*, 63–70. [CrossRef] [PubMed]
- 42. Lonsdale, D.; Lonsdale, M.D.S. Handling and communicating intelligence information: A conceptual, historical and information design analysis. *Intell. Natl. Secur.* **2019**, *34*, 703–726. [CrossRef]
- 43. Lipton, R. The Practical Guide to Information Design; John Wiley & Sons: Hoboken, NJ, USA, 2011.
- 44. Medicines.org.uk. About Emc—Electronic Medicines Compendium (emc). Emc, 2019. Available online: https://www.medicines.org.uk/emc/about-the-emc (accessed on 20 October 2019).
- 45. Foley, M.; Harris, R.; Rich, E.; Rapca, A.; Bergin, M.; Norman, I.; Van Hout, M.-C. The availability of over-the-counter codeine medicines across the European Union. *Public Health* **2015**, *129*, 1465–1470. [CrossRef]
- 46. Dickinson, D.; Raynor, D.K.; Duman, M. Patient information leaflets for medicines: Using consumer testing to determine the most effective design. *Patient Educ. Couns.* **2001**, *43*, 147–159. [CrossRef]
- Campbell, C.I.; Weisner, C.; LeResche, L.; Ray, G.T.; Saunders, K.; Sullivan, M.D.; Banta-Green, C.; Merrill, J.O.; Silverberg, M.J.; Boudreau, D.; et al. Age and Gender Trends in Long-Term Opioid Analgesic Use for Noncancer Pain. *Am. J. Public Health* 2010, 100, 2541–2547. [CrossRef]
- Omega Pharma Ltd. Solpadeine Plus Capsules. [image]. Electronic Medicines Compendium. 2017. Available online: https://www.medicines.org.uk/emc/product/6486/smpc (accessed on 20 October 2019).
- 49. Thornton & Rose Ltd. Thornton & Rose ltd. [image]. Electronic Medicines Compendium. 2018. Available online: https://www.medicines.org.uk/emc/product/4825/smpc (accessed on 20 October 2019).
- 50. Surber, T.R. The effect of text expectation, subject matter and passage length on study tactics and retention. *Read. Res. Instruct.* **1992**, *31*, 32–40.
- 51. An, J.; Kim, S.J.; Park, S.; Moon, K.T.; Park, E.-C. The effects of patient education on patient safety: Can we change patient perceptions and attitudes?: Lessons from the Armed Forces Capital Hospital in Korea. *Int. J. Qual. Health Care* **2017**, *29*, 392–398. [CrossRef]
- 52. Maat, H.P.; Lentz, L. Improving the usability of patient information leaflets. *Patient Educ. Couns.* **2010**, *80*, 113–119. [CrossRef] [PubMed]
- 53. Dolk, S.; Lentz, L.; Knapp, P.; Maat, H.P.; Raynor, T. Headline section in patient information leaflets: Does it improve reading performance and perception? *Inf. Des. J.* **2011**, *19*, 46–57. [CrossRef]
- 54. Lonsdale, M.; Lonsdale, D.; Lim, H. The impact of neglecting user-centred information design principles when delivering online information. *Inf. Des. J.* **2018**, *24*, 151–177.
- 55. Teo, C.H.; Ng, C.J.; White, A. What Do Men Want from a Health Screening Mobile App? A Qualitative Study. *PLoS ONE* **2017**, *12*, e0169435. [CrossRef] [PubMed]
- 56. Kirby, T. The end of over-the-counter codeine in Australia. Lancet Psychiatry 2018, 5, 395. [CrossRef]
- 57. Cairns, R.; Schaffer, A.L.; Brown, J.A.; Pearson, S.; Buckley, N.A. Codeine use and harms in Australia: Evaluating the effects of re-scheduling. *Addict.* **2019**, *115*, 451–459. [CrossRef]

- 58. Doak, C.C.; Doak, L.G.; Root, J.H. Teaching Patients with Low Literacy Skills. *AJN Am. J. Nurs.* **1996**, *96*, 16M. [CrossRef]
- 59. Masulli, F.; Galluccio, M.; Gerard, C.-L.; Peyre, H.; Rovetta, S.; Bucci, M.P. Effect of different font sizes and of spaces between words on eye movement performance: An eye tracker study in dyslexic and non-dyslexic children. *Vis. Res.* **2018**, *153*, 24–29. [CrossRef]
- 60. Pirès, C.; Vigário, M.; Cavaco, A. Graphical content of medicinal package inserts: An exploratory study to evaluate potential legibility issues. *Health Inf. Libr. J.* **2015**, *33*, 121–139. [CrossRef]
- 61. Ling, J.; Van Schaik, P. The influence of font type and line length on visual search and information retrieval in web pages. *Int. J. Hum.-Comput. Stud.* **2006**, *64*, 395–404. [CrossRef]
- 62. Moore, S. Read All About It: Health Literacy and Veterinary Client Educational Materials. *Top. Companion Anim. Med.* **2018**, *33*, A2. [CrossRef] [PubMed]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).